Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
2.

Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL.

Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27.

3.

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL.

Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.

4.

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL.

Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Review.

5.

His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display.

Koho T, Ihalainen TO, Stark M, Uusi-Kerttula H, Wieneke R, Rahikainen R, Blazevic V, Marjomäki V, Tampé R, Kulomaa MS, Hytönen VP.

Eur J Pharm Biopharm. 2015 Oct;96:22-31. doi: 10.1016/j.ejpb.2015.07.002. Epub 2015 Jul 10.

PMID:
26170162
6.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL.

Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

7.

Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Malm M, Tamminen K, Lappalainen S, Uusi-Kerttula H, Vesikari T, Blazevic V.

Clin Vaccine Immunol. 2015 Jun;22(6):656-63. doi: 10.1128/CVI.00015-15. Epub 2015 Apr 22.

8.

High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children.

Malm M, Uusi-Kerttula H, Vesikari T, Blazevic V.

J Infect Dis. 2014 Dec 1;210(11):1755-62. doi: 10.1093/infdis/jiu361. Epub 2014 Jun 26.

PMID:
24970849
9.

Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays.

Uusi-Kerttula H, Tamminen K, Malm M, Vesikari T, Blazevic V.

Microbes Infect. 2014 Jun;16(6):472-80. doi: 10.1016/j.micinf.2014.02.010. Epub 2014 Mar 14.

PMID:
24631874
10.

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

Coughlan L, Uusi-Kerttula H, Ma J, Degg BP, Parker AL, Baker AH.

Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11.

PMID:
24617540
11.

Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.

Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, Uusi-Kerttula H, Zagordi O, Belshe RB, Frey SE, Tumpey TM, García-Sastre A.

Sci Transl Med. 2013 May 29;5(187):187ra70. doi: 10.1126/scitranslmed.3005996.

Supplemental Content

Loading ...
Support Center